Johnson & Johnson
JNJ · NYSE
JNJ · NYSE
Johnson & Johnson sells healthcare products through its Innovative Medicine and MedTech businesses. Innovative Medicine develops and commercializes prescription drugs, including oncology treatments such as Darzalex and Erleada, while MedTech supplies surgical, cardiovascular, orthopaedic, and other medical technologies, including the OTTAVA robotic surgery system. Its customers include healthcare providers, hospitals, distributors, patients, and consumers. The company generated $94.2 billion of revenue and $26.8 billion of net income in FY2025, compared with $88.8 billion of revenue and $14.1 billion of net income in FY2024. The supplied evidence does not state the current revenue contribution of each segment.
Johnson & Johnson fell $11.80, or 4.42%, from $266.73 to $254.93 over the week. The decline was concentrated in the $9.71 drop on July 30, followed by a modest rebound on July 31, another $1.94 loss on August 3, and a $0.52 recovery on August 4. The supplied evidence does not identify a dated earnings release, guidance change, or other company-specific shock that explains the move. Instead, market context included a Dow milestone and an AI-driven technology sell-off, with JNJ cited among non-technology blue chips supported by earnings growth. Positive company themes—oncology growth, OTTAVA commercialization, and a reported JNJ-GSK deal—did not prevent the stock from weakening.
